Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Minelli

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Cancers|September 3, 2020
Evaluation of Prognostic Factors for Survival in Transverse Colon CancerMichela Roberto, Giulia Arrivi, Francesca Lo Bianco, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective StudyCarlo Signorelli, Maria Alessandra Calegari, Michele Basso, et al.
Clinical Colorectal Cancer|January 24, 2025
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter CohortJessica Lucchetti, Lorenzo Angotti, Alessandro Parisi, et al.
Cancers|December 23, 2023
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup AnalysisCarlo Signorelli, Mario Giovanni Chilelli, Diana Giannarelli, et al.
Zookeys|February 25, 2015
Italian natural history museums on the verge of collapse?Franco Andreone, Luca Bartolozzi, Giovanni Boano, et al.
Cancers|October 29, 2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA StudyCarlo Signorelli, Michele Basso, Maria Alessandra Calegari, et al.
Cancers|June 26, 2025
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA StudyCarlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, et al.
Current Oncology (Toronto, Ont.)|December 27, 2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA StudyCarlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, et al.
Plos One|June 1, 2012
New species in the Old World: Europe as a frontier in biodiversity exploration, a test bed for 21st century taxonomyBenoît Fontaine, Kees van Achterberg, Miguel Angel Alonso-Zarazaga, et al.
Biodiversity Data Journal|October 23, 2015
PESI - a taxonomic backbone for EuropeYde de Jong, Juliana Kouwenberg, Louis Boumans, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Cancers|September 3, 2020
Evaluation of Prognostic Factors for Survival in Transverse Colon CancerMichela Roberto, Giulia Arrivi, Francesca Lo Bianco, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective StudyCarlo Signorelli, Maria Alessandra Calegari, Michele Basso, et al.
Clinical Colorectal Cancer|January 24, 2025
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter CohortJessica Lucchetti, Lorenzo Angotti, Alessandro Parisi, et al.
Cancers|December 23, 2023
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup AnalysisCarlo Signorelli, Mario Giovanni Chilelli, Diana Giannarelli, et al.
Zookeys|February 25, 2015
Italian natural history museums on the verge of collapse?Franco Andreone, Luca Bartolozzi, Giovanni Boano, et al.
Cancers|October 29, 2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA StudyCarlo Signorelli, Michele Basso, Maria Alessandra Calegari, et al.
Cancers|June 26, 2025
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA StudyCarlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, et al.
Current Oncology (Toronto, Ont.)|December 27, 2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA StudyCarlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, et al.
Plos One|June 1, 2012
New species in the Old World: Europe as a frontier in biodiversity exploration, a test bed for 21st century taxonomyBenoît Fontaine, Kees van Achterberg, Miguel Angel Alonso-Zarazaga, et al.
Biodiversity Data Journal|October 23, 2015
PESI - a taxonomic backbone for EuropeYde de Jong, Juliana Kouwenberg, Louis Boumans, et al.
Pageof 7